Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The politicization of oncology drug funding reviews in Canada.

Literature DB >> 27330341

The politicization of oncology drug funding reviews in Canada.

C Skedgel¹, T Younis².

Abstract

Year: 2016 PMID： 27330341 PMCID： PMC4900824 DOI： 10.3747/co.23.3126

Source DB: PubMed Journal: Curr Oncol ISSN： 1198-0052 Impact factor: 3.677

× No keyword cloud information.

14 in total

1. Rationing healthcare: the appeal of muddling through elegantly.

Authors: D J Hunter
Journal: Healthc Pap Date: 2001

2. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

Authors: Sheila M Rothman; Victoria H Raveis; Anne Friedman; David J Rothman
Journal: Am J Public Health Date: 2011-01-13 Impact factor: 9.308

3. The rationing debate. Rationing within the NHS should be explicit. The case for.

Authors: L Doyal
Journal: BMJ Date: 1997-04-12

Review 4. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?

Authors: Heather McDonald; Cathy Charles; Laurie Elit; Amiram Gafni
Journal: Pharmacoeconomics Date: 2015-03 Impact factor: 4.981

5. Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

Authors: J S Hoch; M Sabharwal
Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677

6. Dilemmas in rationing health care services: the case for implicit rationing.

Authors: D Mechanic
Journal: BMJ Date: 1995-06-24

7. Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage.

Authors: Julia Abelson; Patricia A Collins
Journal: Healthc Policy Date: 2009-02

Review 8. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Authors: Christopher M Booth; George Dranitsaris; M Corona Gainford; Scott Berry; Michael Fralick; John Fralick; Joanna Sue; Mark Clemons
Journal: BMC Cancer Date: 2007-06-28 Impact factor: 4.430

9. Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Authors: Jeffrey S Hoch; Jaclyn Beca; Mona Sabharwal; Scott W Livingstone; Anthony L A Fields
Journal: Pharmacoeconomics Date: 2015-08 Impact factor: 4.981

The politicization of oncology drug funding reviews in Canada.

1. Rationing healthcare: the appeal of muddling through elegantly.

2. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

3. The rationing debate. Rationing within the NHS should be explicit. The case for.

Review 4. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?

5. Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.

6. Dilemmas in rationing health care services: the case for implicit rationing.

7. Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage.

Review 8. External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

9. Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

10. The timing of drug funding announcements relative to elections: a case study involving dementia medications.

1. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.

2. Timeliness of the oncology drug review process for public funding in Canada.

3. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.

4. Determinants of the Cancer Drug Funding Process in Canada.